全文获取类型
收费全文 | 1371860篇 |
免费 | 100148篇 |
国内免费 | 5528篇 |
专业分类
耳鼻咽喉 | 19993篇 |
儿科学 | 40702篇 |
妇产科学 | 39089篇 |
基础医学 | 191614篇 |
口腔科学 | 40605篇 |
临床医学 | 117576篇 |
内科学 | 267637篇 |
皮肤病学 | 30609篇 |
神经病学 | 108055篇 |
特种医学 | 55068篇 |
外国民族医学 | 452篇 |
外科学 | 212194篇 |
综合类 | 37812篇 |
现状与发展 | 18篇 |
一般理论 | 447篇 |
预防医学 | 94700篇 |
眼科学 | 32631篇 |
药学 | 103865篇 |
60篇 | |
中国医学 | 5355篇 |
肿瘤学 | 79054篇 |
出版年
2018年 | 13189篇 |
2016年 | 11816篇 |
2015年 | 13742篇 |
2014年 | 19027篇 |
2013年 | 27414篇 |
2012年 | 35995篇 |
2011年 | 38176篇 |
2010年 | 22837篇 |
2009年 | 21994篇 |
2008年 | 35705篇 |
2007年 | 38734篇 |
2006年 | 39350篇 |
2005年 | 37784篇 |
2004年 | 36346篇 |
2003年 | 35169篇 |
2002年 | 34499篇 |
2001年 | 64346篇 |
2000年 | 66029篇 |
1999年 | 56139篇 |
1998年 | 15145篇 |
1997年 | 13910篇 |
1996年 | 13294篇 |
1995年 | 12532篇 |
1994年 | 11785篇 |
1992年 | 42959篇 |
1991年 | 41446篇 |
1990年 | 40691篇 |
1989年 | 39716篇 |
1988年 | 37076篇 |
1987年 | 36510篇 |
1986年 | 34942篇 |
1985年 | 33160篇 |
1984年 | 24860篇 |
1983年 | 21074篇 |
1982年 | 12684篇 |
1981年 | 11592篇 |
1979年 | 23948篇 |
1978年 | 17077篇 |
1977年 | 14839篇 |
1976年 | 13389篇 |
1975年 | 15270篇 |
1974年 | 18087篇 |
1973年 | 17563篇 |
1972年 | 16812篇 |
1971年 | 15717篇 |
1970年 | 14915篇 |
1969年 | 14347篇 |
1968年 | 13460篇 |
1967年 | 12017篇 |
1966年 | 11259篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
61.
目的 分析微滴式数字PCR(droplet digital PCR, ddPCR)和实时荧光定量PCR(quantitative real-time PCR,qPCR)的核酸检测结果,比较两种方法检测各类样本的差异性,为改进新型冠状病毒核酸检测方案提供数据支持。 方法 利用ddPCR和qPCR技术对已经确诊的3例新型冠状病毒肺炎患者发病不同时间的全血、尿液、粪便共22份标本进行新型冠状病毒核酸检测。 结果 两种方法对人保守区域基因扩增结果一致:全血标本信号最强,尿液次之,粪便最少;ddPCR在1份全血,1份尿液,5份粪便中检出ORF-1ab和N基因的阳性微滴,qPCR仅在3份粪便中检出上述基因,漏检的3个标本基因拷贝数平均浓度为128 copies/ml;ddPCR在发病<5、5~15、>15 d的各类标本中都有检出,qPCR检出以中晚期为主;重症病例用ddPCR均可测到阳性微滴,qPCR检测的各类标本均为阴性;轻症病例的各类标本中qPCR只有粪便核酸检测阳性,ddPCR检出率高于qPCR。 结论 ddPCR可以有效克服qPCR 灵敏度不足的难题,是对qPCR 的有益补充,尤其是针对病毒载量比较低的血液、尿液和可疑的粪便或肛拭子标本,适用于早期感染的判断及患者治愈后出院诊断。 相似文献
62.
63.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
64.
E. M. Peterman C. Sullivan M. F. Goody I. Rodriguez-Nunez J. A. Yoder C. H. Kim 《Infection and immunity》2015,83(1):430-440
Mitochondria are known primarily as the location of the electron transport chain and energy production in cells. More recently, mitochondria have been shown to be signaling centers for apoptosis and inflammation. Reactive oxygen species (ROS) generated as by-products of the electron transport chain within mitochondria significantly impact cellular signaling pathways. Because of the toxic nature of ROS, mitochondria possess an antioxidant enzyme, superoxide dismutase 2 (SOD2), to neutralize ROS. If mitochondrial antioxidant enzymes are overwhelmed during severe infections, mitochondrial dysfunction can occur and lead to multiorgan failure or death. Pseudomonas aeruginosa is an opportunistic pathogen that can infect immunocompromised patients. Infochemicals and exotoxins associated with P. aeruginosa are capable of causing mitochondrial dysfunction. In this work, we describe the roles of SOD2 and mitochondrial ROS regulation in the zebrafish innate immune response to P. aeruginosa infection. sod2 is upregulated in mammalian macrophages and neutrophils in response to lipopolysaccharide in vitro, and sod2 knockdown in zebrafish results in an increased bacterial burden. Further investigation revealed that phagocyte numbers are compromised in Sod2-deficient zebrafish. Addition of the mitochondrion-targeted ROS-scavenging chemical MitoTEMPO rescues neutrophil numbers and reduces the bacterial burden in Sod2-deficient zebrafish. Our work highlights the importance of mitochondrial ROS regulation by SOD2 in the context of innate immunity and supports the use of mitochondrion-targeted ROS scavengers as potential adjuvant therapies during severe infections. 相似文献
65.
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related mortality within the next decade, with limited effective treatment options and a dismal long-term prognosis for patients. Genomic profiling has not yet manifested clinical benefits for diagnosis, treatment or prognosis in PDAC, due to the lack of available tissues for sequencing and the confounding effects of low tumour cellularity in many biopsy specimens. Increasing focus is now turning to the use of minimally invasive liquid biopsies to enhance the characterisation of actionable PDAC tumour genomes. Circulating tumour DNA (ctDNA) is the most comprehensively studied liquid biopsy analyte in blood and can provide insight into the molecular profile and biological characteristics of individual PDAC tumours, in real-time and in advance of traditional imaging modalities. This can pave the way for identification of new therapeutic targets, novel risk variants and markers of tumour response, to supplement diagnostic screening and provide enhanced scrutiny in treatment stratification. In the roadmap towards the application of precision medicine for clinical management in PDAC, ctDNA analyses may serve a leading role in streamlining candidate biomarkers for clinical integration. In this review, we highlight recent developments in the use of ctDNA-based liquid biopsies for PDAC and provide new insights into the technical, analytical and biological challenges that must be overcome for this potential to be realised. 相似文献
66.
67.
68.
69.
70.